The US Food and Drug Administration (FDA) announces new regulatory guidelines for future COVID-19 vaccines and booster shots. Moderna (MRNA) and Pfizer (PFE) shares move higher on this news, while Novavax (NVAX) takes a dip.

A new FDA framework for Covid-19 vaccines created confusion among physicians about what it means for young children

The Food and Drug Administration will issue new guidelines requiring stiffer clinical trials prior to the approval of new COVID boosters.

Leaders at the FDA, HHS and elsewhere are putting guardrails around COVID-19 boosters, which could mean delayed shots or eligibility changes this fall.

The World Health Organization's member countries have approved an agreement to better prevent, prepare for and respond to future pandemics in the wake of the devastation wrought by the coronavirus.

By Kamal Choudhury (Reuters) -Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S. regulatory approval for its COVID-19 vaccine, albeit with new conditions, which helped allay some investor concerns over the future of the shot.

Since the COVID-19 pandemic, there has been a decline in U.S. vaccine uptake, while widespread misinformation and distrust make it challenging to craft effective public health responses.

A former Pfizer scientist said the timing of the 2020 vaccine results “wasn’t a coincidence,” according to allegations provided by a rival drugmaker.